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Profiles of miRNA Isoforms and 
tRNA Fragments in Prostate Cancer
Rogan G. Magee, Aristeidis G. Telonis  , Phillipe Loher, Eric Londin & Isidore Rigoutsos  
MicroRNA (miRNA) isoforms (“isomiRs”) and tRNA-derived fragments (“tRFs”) are powerful regulatory 
non-coding RNAs (ncRNAs). In human tissues, both types of molecules are abundant, with expression 
patterns that depend on a person’s race, sex and population origin. Here, we present our analyses of the 
Prostate Cancer (PRAD) datasets of The Cancer Genome Atlas (TCGA) from the standpoint of isomiRs 
and tRFs. This study represents the first simultaneous examination of isomiRs and tRFs in a large 
cohort of PRAD patients. We find that isomiRs and tRFs have extensive correlations with messenger 
RNAs (mRNAs). These correlations are disrupted in PRAD, which suggests disruptions of the regulatory 
network in the disease state. Notably, we find that the profiles of isomiRs and tRFs differ in patients 
belonging to different races. We hope that the presented findings can lay the groundwork for future 
research efforts aimed at elucidating the functional roles of the numerous and distinct members of 
these two categories of ncRNAs that are present in PRAD.
The rapidly decreasing cost of next generation sequencing has enabled the unbiased profiling of short and long 
non-coding RNAs (ncRNAs) in many settings. This has facilitated the quantification of select RNAs under a 
variety of conditions, the discovery of new categories of transcripts, and the identification of new members of 
previously established categories1,2. In this report, we focus on two specific categories of ncRNAs: the isoforms 
of microRNAs (miRNAs), or isomiRs, and fragments that are derived from transfer RNAs (tRNAs), or tRFs. We 
examine the profiles of isomiRs and tRFs in the PRAD samples that are available in the TCGA repository.
MiRNAs are ~22 nucleotide (nt) long non-coding RNAs3 that derive from hairpin-shaped precursor tran-
scripts. They promote the degradation of sequence-matched mRNA targets or inhibit their translation4–8. The pre-
cursors of miRNAs were initially thought to produce at most a single mature product from each hairpin arm9,10. 
It is now known that miRNA precursor arms give rise to many distinct isoforms, termed “isomiRs”11,12. Any two 
isomiRs from the same miRNA arm typically differ in either their 5′ termini, 3′ termini, or both. In previous 
work, we showed that the most abundant isoform is frequently different from the one annotated as the “canonical” 
or “archetypal” sequence13 that is found in public databases like miRBase9,14. 
In previous work, we analyzed hundreds of transcriptomic datasets from LCL samples and showed that 
isomiRs are produced constitutively and are differentially abundant among people in a manner that depends 
on the individuals’ sex, population origin, and race13. We also showed that similar isomiR dependencies exist 
in the context of breast cancer and demonstrated experimentally that isomiRs from the same hairpin arm can 
target largely distinct sets of mRNAs15. We also examined whether isomiR profiles differ across cancer types. We 
analyzed 10,271 cancer samples from TCGA that represent 32 cancer types and found that by simply examin-
ing whether an isomiR is present or absent in a sample, we could build highly sensitive and specific biomarkers 
that distinguish among the 32 cancer types16. In the case of PRAD, we showed that isomiRs can correctly clas-
sify TCGA datasets (obtained by the Illumina platform) as well as datasets obtained from two other platforms 
(Affymetrix, and ABI SOLiD)16.
tRFs represent a new class of short regulatory non-coding RNAs that were recently discovered through analy-
sis of short RNA sequencing data17–19. tRFs are relatively short RNA oligonucleotides, with lengths ranging from 
18 to ~34 nt. In this presentation, we study only tRFs that overlap with mature tRNAs. These can be grouped into 
five classes17,18,20–22: 5′-tRFs, i-tRFs, 3′-tRFs, 5′-tRNA halves (5′-tRHs), and 3′-tRNA halves (3′-tRHs).
Several proteins have been implicated in the production of tRFs. Chronologically first, Angiogenin was shown 
to be a producer of tRNA halves under stress conditions17,21–23. RNAse Z produces tRFs derived from premature 
tRNA transcripts24. Finally, the miRNA-producing enzyme Dicer has also been implicated in the production 
of tRFs in several species24–27, but many tRFs are also produced independently of Dicer27. In complete analogy 
to isomiRs, we showed that tRFs are produced constitutively and are differentially abundant among people in a 
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manner that depends on the individuals’ sex, population origin, and race as well as on tissue, and disease sub-
type20. Functionally, tRFs have also been reported to increase in abundance after hepatitis B and C infection28, to 
act as miRNAs26, to act as molecular decoys of an RNA binding protein29, to mediate neuroprotective responses30, 
to inhibit angiogenesis after ischemic injury31, and to be involved in sex-hormone pro-proliferative signaling23. 
Collectively, these results suggest important functional roles for these molecules.
Recent work by the TCGA PRAD Consortium has improved our understanding of the biochemistry of pros-
tate cancer subtypes32, but many questions regarding the biochemical progression of the disease remain unan-
swered33–37. Several of the currently open questions include the identification of new and potentially actionable 
biochemical targets for treatment, the relative merit of treatment vs. active surveillance38, the relevance of race in 
establishing risk, and the impact of race in disease prognosis33,39,40. To date, and to the best of our knowledge, the 
significance of isomiRs and tRFs has not been studied systematically in PRAD.
In this study, we characterize the expression of isomiRs and tRFs in the context of PRAD. Specifically, we 
investigate the possibility of associations between clinical categories of PRAD and the expression of isomiRs and 
tRFs, and report on whether these ncRNAs are associated with disease progression.
Results
Patients, samples, and sequencing limitations. 526 samples were obtained from 472 patient donors. 
The patients span a range of ages and several races (Table 1). These samples form evenly sized subgroups from the 
standpoint of Gleason score at initial diagnosis (Table 1). It is important to note here that short RNA-seq for the 
TCGA project was capped at 30 cycles of sequencing. This choice does not pose a problem for miRNAs and their 
isoforms, because their typical length is ~22 nt. However, in the case of tRFs, the 30-cycle limit prevents us from 
identifying and quantitating longer molecules, such as the 5′-tRHs and 3′-tRHs41.
Prostate isomiRs - summary statistics. For each sample in turn, we used Threshold-seq42 (see Methods) 
to automatically determine a dataset-dependent, adaptive threshold. Using these thresholds across the 526 data-
sets, we identified 3,178 isomiRs that were used in the subsequent analyses. Each of these 3,178 isomiRs exceeded 
Threshold-seq’s threshold in at least one of the analyzed datasets. 3,104 of these isomiRs are unambiguously 
annotated in our analyses, i.e. they map to a single mature miRNA or miRNA precursor, whereas the remaining 
74 map to a total of 28 miRNA loci with known paralogues in the human genome. The 3,104 isomiRs arise from 
600 distinct miRNA precursor arms (Fig. 1A) that correspond to 391 unique miRNA loci.
The isomiRs in TCGA PRAD have lengths that are typical of mature miRNAs. The most frequently encoun-
tered isomiR length is 22 nt, followed closely by 21 nt (Fig. 1B). Moreover, the endpoints of isomiRs (Fig. 1C) fol-
low essentially the same distributions that we reported in our prior work15. We note that nearly one half (43.0%) 
of all identified isomiRs have 5′ termini that differ from the 5′ termini of the miRNA sequences found in miRBase, 
in agreement with what we found previously in a different tissue13. IsomiRs with different 5′ termini have differ-
ent seed sequences compared to the archetype in miRBase, and, thus, different mRNA targets than the arche-
type15,43–45. Consequently, the identification of so many isomiRs with 5′ termini is of high potential importance, 
as it suggests the existence of a large repertoire of genes targeted by miRNAs that have not been explored to date. 
Moreover, 73.3% of the isomiRs have 3′ termini that differ from the 3′ termini of the corresponding archetypes 
found in miRBase.
Across all miRNA precursors, a few arms appear to be the greatest producers of distinct isomiRs in the PRAD 
context: 42 isomiRs are produced from miR-143-3p, 41 from miR-182-5p, 40 from miR-21-5p, 36 from miR-
183–5p, 36 from miR-10a-5p, and 33 from let-7a-5p. (Fig. 1D). Supp. Table 1 lists all of the mature miRNAs that 
produce more than one isomiR above threshold in at least one of the analyzed datasets.
Prostate tRFs – summary statistics. We mined the sequenced reads using our MINTmap tRF mining 
method41, then used the Threshold-seq method42 to determine which tRFs to retain for each dataset. Across 
the 526 TCGA PRAD datasets, we identified 6,296 distinct tRFs that pass threshold in at least one dataset. Of 
these, 3,903 (62.0%) arise from nuclearly-encoded tRNAs, whereas the remaining 2,393 (38.0%) arise from 
Sample Characteristics (n = 526)
Race
White 431 Normal Tissue < 6 50
Black_or_African_American 63 Tumor Tissue 476
Asian 12 Gleason Score
American_Indian_or_Alaska_Native 1 3 + 3, 2 + 4 48, 1
[Not_Available] 19 3 + 4 143
Age at diagnosis
40–49 27 4 + 3 93
50–59 166 4 + 4, 5 + 3, 3 + 5 54, 6, 8
60–69 230 4 + 5, 5 + 4 67, 45
70+ 49 5+5 11
Table 1. Clinical characteristics of prostate cancer samples. 526 white-listed samples were analyzed from The 
Cancer Genome Atlas collection of patients with prostate cancer. 472 patients contributed these samples. Race 
characteristics as reported in TCGA clinical patient data Biotab files downloaded on January 29, 2016 are 
shown. Also shown are age characteristics and the Gleason grade by histological examination.
www.nature.com/scientificreports/
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mitochondrially-encoded tRNAs. In other words, the 22 mitochondrial (MT) tRNAs contribute almost half as 
many unique tRFs as do the 610 nuclear tRNAs, a rather unexpected finding. 140 tRFs show non-zero expression 
across all 526 (100%) datasets, which suggests possible relevance of tRFs for PRAD biology. Moreover, 83 tRFs 
show a normalized mean abundance at least as high as 10 reads per million (RPM), in either normal or prostate 
cancer samples.
Prostate tRFs – lengths, structural categories, source isoacceptors. The majority (66%) of the 
6,296 tRFs are i-tRFs20, i.e. they overlap the interior of the mature tRNA sequence. Interestingly, nearly one half 
(42%) of all i-tRFs are produced by MT tRNAs, a disproportionately high contribution considering that there are 
only 22 MT tRNA sequences. The remainder of the tRFs are almost evenly split among nuclear 5′-tRFs, nuclear 
3′-tRFs, and mitochondrial 3′-tRFs (Fig. 2A). Interestingly, five isoacceptors contribute 44% all of the tRFs we 
identified in PRAD. They are: Leucine (Leu), Glycine (Gly), Histidine (His), Glutamine (Gln), and Glutamic 
acid (Glu) (Fig. 2B). The lengths of nuclearly-encoded tRFs differ characteristically from those of MT-encoded 
tRFs (Fig. 2C). This is similar to what we observed previously in other human tissues20. Nuclearly-encoded tRFs 
appear to favor shorter lengths (16–20 nt), whereas mitochondrially-encoded tRFs tend to favor specific and 
generally-longer lengths (17, 21, 26, and 29 nt) (Fig. 2C).
Prostate isomiRs, prostate tRFs, and comparisons to clinical characteristics. Tissue state. When 
we compared tumor and normal samples, we observed marked differences in the lengths of tRFs from the struc-
tural categories described above. We computed density functions for the probability of encountering a tRF of 
length X in each structural category, and included genome of origin (nuclear or mitochondrial) as an additional 
variable. For several lengths, we found statistically-significant (Mann-Whitney U-test) differences between nor-
mal and tumor. Figure 3 shows these findings. In it, a few representative cases are highlighted in the plots with 
asterisks. Individual differences between structural categories appear to be specific to the tissue and tissue-state 
combination. For example, in TCGA’s breast cancer (BRCA) samples, we found short (18–20 nt) 5′-tRFs to be 
more prevalent in the tumor samples20. Unlike BRCA, in TCGA PRAD, 5′-tRFs with these lengths are more prev-
alent in the normal samples. Additionally, 3′-tRFs also tend to be short (18–20 nt) in normal prostate samples, 
which is again unlike what we found in normal breast. Finally, we note that 3′-tRFs from mitochondrially-derived 
tRNAs differ between normal prostate and tumor by length: short (19 nt) tRFs are more frequent in normal sam-
ples, whereas longer (23 nt) tRFs are more frequent in prostate tumor samples.
Figure 1. Classification of isomiRs by mature miRNA, length and endpoint. We collected 3,178 isomiRs from 
the pool of 526 TCGA PRAD samples. (A) The number of mature miRNAs which give rise to N isomiRs (N 
ranges from 1 to 40). (B) The number of isomiRs of each specific possible length from 16–30 nt within these 
data. (C) The number of isomiRs having different 5′ and 3′ endpoints with respect to the archetype miRNA’s 
endpoints. Note that this panel is restricted and shows only endpoints that differ by at most 3 nt from the 
endpoints of the archetype. (D) The top-11 miRNA loci producing 25 or more isomiRs.
www.nature.com/scientificreports/
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Tissue state and patient race. We next used Significance Analysis of Microarrays (SAM)46 to compare the abun-
dance of isomiRs and tRFs, respectively, across tissue states (both races) and across tissue states within each race 
group in turn. We retained only isomiRs or tRFs that were differentially abundant and had an associated False 
Discovery Rate (FDR) of 5% (Supp. Table 2). Of 3,178 isomiRs, 524 are differentially abundant between PRAD 
and normal prostate in both Black or African American patients (B/Aa) and White (Wh) patients (Fig. 4A). A 
larger number of isomiRs (1,519) are differentially abundant in PRAD vs. normal comparisons, exclusively in 
Wh patients. We also analyzed the 6,296 tRFs and found 35 tRFs to be differentially abundant between PRAD 
and normal in both Wh and B/Aa patients (Fig. 4B). A much larger portion comprising 3,307 tRFs is differen-
tially abundant exclusively in Wh patients. Interestingly, 119 tRFs are exclusively differentially abundant between 
PRAD Wh and PRAD B/Aa.
Gleason score and prognostic group. In order to determine whether the profiles of tRFs or isomiRs are asso-
ciated with progression of disease, we performed multi-class SAM analysis with the Gleason score and the 
newly-proposed five-grade prognostic system (Supp. Table 2)47. We used only samples for which Gleason score 
agreed in both clinical and pathologic grading (n = 518 samples), and also kept normal samples (with Gleason 
score lower than 6) in the comparisons. In these analyses, we maintained the FDR threshold at 5%. We found that 
n = 2,441 isomiRs and n = 4,331 tRFs are differentially abundant between Gleason-score subgroups. We find that 
n = 2,493 and 4,652 isomiRs and tRFs are differentially abundant when we instead reclassify tumors using the 
alternative five-grade system. Importantly, the identified groups of isomiRs and tRFs are highly congruent: the 
same n = 2,401 isomiRs and n = 4,187 tRFs arise from both of these two independent analyses. Though prognos-
tic groups are based on Gleason score, the subgroups do differ in that the samples of Gleason score 7 are split into 
two categories, each of which is characterized by a different prognosis. The respective isomiR and tRF profiles do 
differ between these two groups. All of these isomiRs and tRFs are shown in Supp. Table 2.
Figure 2. Classification of tRFs by isodecoder and genome of origin. (A) Percentage of tRFs that map to a 
specific structural category (nuclearly- and MT-derived tRFs are shown separately). (B) Percentage of tRFs 
that arise from isodecoders of specific amino acids. (C) Distribution of tRFs as a function of length (nuclearly- 
and MT-derived tRFs are shown separately). The whiskers represent standard error of the mean  across 
samples. Nuc: nuclear. MT: mitochondrial.
www.nature.com/scientificreports/
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Using the abundance of all isomiRs from a miRNA locus as a proxy for isomiR profiles. 
Quantitative RT-PCR (qRT-PCR) methods such as Taqman miRNA qPCR and Exiqon LNA miRCuRY are 
designed with an eye towards distinguishing among miRNAs that have base differences that are internal to the 
target sequence. The ability of these methods to distinguish isoforms that differ at their endpoints has been a topic 
of scientific debate. In recent work, we examined both Taqman miRNA qPCR and Exiqon LNA miRCuRY and 
found that these methods cannot distinguish end-point isoforms, in either synthetic or true cellular contexts48. 
While we experimented with isomiRs only, we expect that these findings extend to tRFs as well. Our findings sug-
gest that SYBR Green-based methods are also affected. This includes variants of the SYBR Green method such as 
the one used in a previous B-cell lymphoma study26, which is similar in spirit to the LNA miRCuRY method, but 
without the latter’s additional constraints. Importantly, neither the SYBR Green variant nor the LNA miRCuRY 
can guarantee the specific 5′ and 3′ endpoints of the target.
In light of this limitation, we carried out a second analysis of the deep sequencing data where we aggregated 
the abundance of all isoforms from a given miRNA arm into a single measure. Starting with the pool of isomiRs, 
and for each sample in turn, we summed the RPM values of all isomiRs from each annotated miRNA arm that 
was transcribed. This resulted in 628 observations per sample. Figure 5A–D show boxplots for several miRNA loci 
that showed significant differences between clinical groups (Welch’s independent t-test, p-value ≤ 0.05). In each 
plot, the statistical significance of the shown miRNA arm decreases from left to right. Not more than the top 20 
most significant comparisons are shown in each case.
Using the abundance of all tRFs from a tRNA isoacceptor as a proxy for tRF profiles. As we 
mentioned in the previous section, the current commercially available quantitative methods that target spe-
cific molecules cannot accurately determine the abundance of isomiRs or tRFs. Thus, we repeated the above 
re-analysis, this time for tRFs, wherein we summed up the RPM values of tRFs from the same isoacceptor. This 
resulted in 47 observations per sample. Figure 5E–H show the resulting boxplots (Welch’s independent t-test, 
p-value ≤ 0.05). Again, the statistical significance of the shown isoacceptors decreases from left to right. Not more 
than the top 20 most significant comparisons are shown in each case.
Correlation and anti-correlation of the abundance of prostate isomiRs. We also determined how 
well the levels of individual miRNAs correlate with each other in the context of PRAD tumors. First, we examined 
correlations at the level of the mature miRNA locus. In this case, the abundances of isomiRs from a miRNA locus 
were summed into a single number (see above). We computed the Spearman correlation for all 628 miRNA arms 
Figure 3. Classification of tRFs by length and structural category, in normal and tumor. (A–C) Nuclear tRFs. 
(A) Distribution of 5′-tRFs arising from nuclear tRNAs. 5′-tRFs begin at either the −1 or the +1 position of the 
mature tRNA. (B) Distribution of i-tRFs from nuclear tRNAs. i-tRFs begin after the +1 position and terminate 
within the mature tRNA sequence. (C) 3′-tRFs from nuclear tRNAs. These tRFs begin within the mature 
tRNA and end within the post-transcriptionally-added CCA. (D–F) The counterpart distributions for 5′-tRFs, 
i-tRFs, and 3′-tRFs arising from mitochondrial tRNAs. In all plots, the distributions of tRFs in normal (tumor, 
respectively) samples are shown in green (red, respectively).
www.nature.com/scientificreports/
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that produced one or more isomiRs across the 526 PRAD datasets. We only retained correlations if their absolute 
value was ≥0.75 and FDR ≤ 5% (Supp. Table 3). Figure 6A shows the correlations/anti-correlations at the level 
of the miRNA locus, which survive this filtering. Each node in the network represents an individual miRNA 
arm that produces at least one isomiR. Green edges indicate positive correlations, whereas red edges indicate 
negative correlations. Supp. Table 3 also lists all isomiR-isomiR correlations whose absolute value was ≥0.75 and 
FDR ≤ 5%.
Correlation and anti-correlation of the abundance of prostate tRFs. We repeated the correla-
tion analysis using tRFs this time. As with the miRNAs/isomiRs, we carried out the computations in two ways. 
First, we computed correlations using the summed abundances for tRFs from the various tRNA isoacceptors 
that are active in PRAD (see above). Second, we computed correlations using the individual tRFs. As before, we 
retained only Spearman correlations with absolute value ≥ 0.75 and FDR ≤ 5%. Figure 6B shows the correla-
tions/anti-correlations at the level of the tRNA isoacceptor, which survive this filtering (see Supp. Table 3 for the 
complete list). Each node represents an isoacceptor that produces at least one tRF. Green edges indicate positive 
correlations. Supp. Table 3 also lists all tRF-tRF correlations that survive the correlation and FDR filtering.
Correlation between isomiRs and mRNAs. To investigate the possibility of regulatory networks involv-
ing isomiRs and mRNAs, we selected mRNAs with a mean value of reads per thousand mapped reads (RPKM) 
value that was at most 10 log2 units from the most abundant observed value for ACTB across the 526 samples. 
By design, these mRNAs have average expression that is ≥1/1,024-th of ACTB (210 = 1,024). We retained 9,871 
transcribed mRNAs. Importantly, we used the mRNA RPKM values that are reported in the RSEM normalized 
output that is part of the UNC mRNA pipeline of the TCGA data. Then, we examined the correlation between 
the abundance of these mRNAs and the abundance of isomiRs across all samples. To elucidate potentially mean-
ingful relationships, we limited our focus on the 932 isomiRs that are differentially abundant (according to SAM) 
between normal and tumor samples at FDR = 0% and have median abundance ≥1 RPM. A first set of 210,682 
isomiR-mRNA correlations emerged (Supp. Table 4).
IsomiRs (i.e. miRNAs) interact directly with mRNA transcripts degrading them and leading to a concomitant 
decrease of protein abundance. Such direct interactions are expected to be captured by negatively-correlated 
isomiR-mRNA pairs. On the other hand, positive correlations between miRNAs and mRNAs may reflect indirect 
events downstream of direct targets. In previous work, we showed experimentally that two isomiRs x and y from 
the same miRNA arm can differentially impact the abundance of an mRNA m: transfection of x could lead to a 
decrease in the abundance of m, whereas transfection of y could lead to an increase in the abundance of m, and 
Figure 4. Differentially abundant isomiRs and tRFs in prostate cancer. We used SAM to determine which 
tRFs and isomiRs are differentially abundant at an FDR ≤ 5% in four comparisons: PRAD Wh vs. Normal Wh, 
PRAD B/Aa vs. Normal B/Aa, and PRAD Wh vs. PRAD B/Aa. (A) isomiRs. (B) tRFs. Representative molecules 
from the corresponding group of regulators are also listed. We found no isomiRs or tRFs that are differentially 
abundant between Normal Wh and Normal B/Aa, so these groups are not plotted.
www.nature.com/scientificreports/
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vice versa49. Thus, we computed both positive and negative correlations and list them in Supp. Table 4. There are 
19,812 pairs with a correlation with absolute value ≥ 0.33, including 412 isomiRs and 1,683 mRNAs.
From these correlations with absolute value ≥ 0.33, we sub-selected those from 60 isomiRs from the top five 
isomiR-producing miRNAs shown in Fig. 1D. We combined these with the 12 isomiRs from the 5 miRNA loci 
that participate in the denser networks of the miRNA-miRNA interactions shown in Fig. 6A. We then visualize 
only mRNAs that participate in isomiR-mRNA pairs with ≥15 distinct isomiRs originating from at least two dif-
ferent miRNA loci. Also, we used a single node labeled with the name of the isomiRs’ parental miRNA precursor 
to capture multiple isomiRs. Figure 7A shows the resulting network, which involves 57 isomiRs from 7 miRNA 
loci and 27 mRNAs.
For functional enrichment analysis, we concentrated only on negatively-correlated isomiR-mRNA pairs. These 
pairs were formed by 775 isomiRs and 2,912 mRNAs (Supp. Table 4). Using four different tools (TargetScan50, 
rna2251, miRanda50, RNAhybrid52), we determined which mRNAs were also predicted targets of the isomiRs 
with which they were anti-correlated. For rna22, miRanda, and RNAhybrid, we generated predictions using the 
full-length of the isomiRs of interest and the 3′UTRs of the corresponding anti-correlated mRNA. For Targetscan, 
we used the seed (positions 2–8 of the miRNA) of the corresponding isomiR of interest with the full length of the 
corresponding anti-correlated mRNA. See Supp. Table 4.
We used the target predictions to sub-select the negatively-correlated isomiR-mRNA pairs. Specifically, we 
kept only those mRNAs that were also supported by the 4 target-prediction tools. 310 mRNAs survived this 
filtering (Supp. Table 4). We analyzed them using DAVID and found enrichment for 25 GO terms. The top 5 GO 
terms include: regulation of nucleobase-containing compound metabolism, DNA binding, regulation of nitrogen 
compound metabolic process, regulation of macromolecule biosynthetic process, and regulation of cellular mac-
romolecule biosynthetic process.
For comparison, we also investigated how functional enrichments might change if we used the strength of cor-
relation as a filter, instead of target predictions. Doing so retains 754 mRNAs that are negatively correlated with 
isomiRs at r ≤ −0.33. DAVID analysis revealed 57 GO terms enriched in this group of mRNAs. The correspond-
ing GO terms are listed in Supp. Table 4. The top 5 GO terms include: RNA splicing; mRNA processing; mRNA 
splicing, via spliceosome; RNA splicing, via transesterification reactions with bulged adenosine as nucleophile; 
and RNA splicing, via transesterification reactions.
To assess whether race differences could play a part in these dynamics, we focused on the 196 isomiRs that we 
observed to be differentially abundant between Wh PRAD and B/Aa PRAD (Fig. 4A). We sub-selected among 
Figure 5. Comparison of total RPM at miRNA arms and mature tRNA loci. Separately for each sample, we 
summed the RPM values of each isomiR that arises from a specific locus and assigned the resulting value to that 
locus. There were 628 loci that produced isomiRs in various combinations in the 526 samples. At most 20 of the 
miRNA-arms exhibiting differential abundances are shown in each case, if available. (A) PRAD vs. normal (all 
patients). (B) PRAD vs. normal (Wh patients only). (C) PRAD vs. normal (B/Aa patients only). (D) PRAD from 
Wh patients vs. PRAD from B/Aa patients. (E–H) counterpart plots to (A–D) for isoacceptors. Analogously, we 
summed the RPM values of each tRF that arises from a given isoacceptor, and assigned the resulting value to the 
isoacceptor. There were 47 isoacceptors that produce tRFs in various combinations in the 526 samples. At most 
20 of the isoacceptors exhibiting differential abundances are shown in each case, if available.
www.nature.com/scientificreports/
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all isomiR-mRNA correlations only those associated with these race-dependent isomiRs at r ≤ −0.33, obtaining 
13,230 negatively-correlated isomiR-mRNA pairs. We analyzed the corresponding 93 mRNAs with DAVID and 
found 42 enriched GO terms (Supp. Table 4). Among these terms, we find enrichment for terms such as: cellular 
response to hormone stimulus, reproductive process, reproduction, and multicellular organism reproduction.
Correlation between tRFs and mRNAs. Next, we extended our analysis to correlations involving tRFs 
and mRNAs. We again correlated the expression of the mRNAs identified above with the expression of tRFs across 
all samples, using Spearman correlation. We limited our focus to the 192 tRFs that are differentially abundant 
between normal and tumor samples and have median abundance ≥ 1RPM (Supp. Table 3) and filtered them fur-
ther retaining only those with absolute value ≥ 0.33 and FDR ≤ 5%. We kept both negative and positive correla-
tions, because the mode in which tRFs function has yet to be understood well. As mentioned in the Introduction, 
these ncRNAs have been demonstrated to function as miRNAs – suggesting negative correlations would represent 
functional relationships – but have also been shown to decoy RNA binding proteins – suggesting positive corre-
lations would show functional relationships as well. For presentation purposes, we then collapsed the correlation 
relationships by replacing individual tRF sequences with the name of the tRNA isoacceptor from which they 
arise. This left us with 423 correlation pairs (23 isoacceptors and 223 mRNAs) that are listed in Supp. Table 4. In 
Fig. 7B we depict these pairs. For clarity, we limited our graph and show only those mRNAs that participate in 
≥4 correlations. DAVID analysis of the 223 mRNAs that survived the filtering showed 10 enriched GO terms: 
cellular response to endogenous stimulus, response to endogenous stimulus, response to organic substance, cel-
lular response to hormone stimulus, response to hormone, response to oxygen-containing compound, collagen 
fibril organization, response to organic cyclic compound, response to organonitrogen compound, and response to 
nitrogen compound. Thirteen mRNAs were negatively correlated with tRFs (Supp. Table 4). Removing them from 
the list of 223 mRNAs and repeating the DAVID analysis did not change the list of enriched GO terms. Lastly, 
we examined the mRNAs that were correlated with the 200 tRFs that are differentially abundant between the Wh 
PRAD samples and the B/Aa PRAD samples. We did not find any enriched GO terms in this group.
TCGA PRAD tRFs vs. tRFs obtained from other prostate cancer samples. In previous work20, we 
demonstrated consistent differences in the tRF profiles of individuals that differ by gender, population origin or 
race. This observation thus becomes an important consideration when comparing tRF profiles from samples of 
different origin. With that in mind, we sought to compare our TCGA PRAD tRF profiles with those from two 
different collections of prostate samples for which deep sequencing data is available, but for which neither the 
population origin nor the race of the patient donors is reported. We note here that, by design, the TCGA reposi-
tory comprises samples from individuals whose race is self-reported.
Figure 6. Networks of isomiR-isomiR and tRF-tRF correlations. We collapsed isomiR (tRF, respectively) 
abundance to the corresponding miRNA-arm (tRNA isoacceptor, respectively), and computed Spearman 
correlations among the resulting observations. (A) isomiR-isomiR correlations represented by the 
corresponding miRNA arms. Gold nodes represent miRNAs. (B) tRF-tRF networks as captured by the 
corresponding isoacceptors. In both panels, only correlations with an absolute value ≥ 0.75 and an FDR ≤ 5% 
were retained and shown. Green edges: positive correlations. Red edges: negative correlations.
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The first non-TCGA collection comprises the 11 samples described in earlier work41, a study that sought to 
establish a prostate-cancer-specific tRF signature. An additional characteristic of this collection is that each of 
its 11 samples was created by pooling together samples from multiple patients. The second non-TCGA collec-
tion comprises five normal prostate and five PRAD samples that we generated for a different project16 (available 
at http://trace.ddbj.nig.ac.jp/DRASearch/study?acc = SRP034550). To ensure consistency in the mining steps, 
we analyzed the 21 samples in these two collections using MINTmap and Threshold-seq (see Materials and 
Methods), just as we did for the TCGA PRAD datasets.
Our mining of the 11 datasets of the first collection41 uncovered 3,341 tRFs above Threshold-seq threshold 
in at least one of the samples. Of the 6,296 tRFs that we find in the TCGA PRAD collection, 1,856 (29.48%) are 
also present among the tRFs that MINTmap finds in these 11 samples, and we list them in Supp. Table 5 together 
with their respective universal identifiers, i.e. their license plates, which we described elsewhere53. The Table also 
indicates which of the tRFs are exclusive to tRNA space or can be found in locations of the genome that do not 
harbor tRNAs.
Our mining of the 10 datasets from our parallel project16 uncovered 10,505 tRFs above Threshold-seq’s thresh-
old in at least one of the samples. Of the 6,296 tRFs that we find in the TCGA PRAD collection, 2,090 (33.20%) 
are also present among the tRFs found in this collection and are listed in Supp. Table 5.
Finally, we compared all three of these collections and found 923 tRFs that are present consistently in all of 
them. Considering the potential diversity of the patients who contributed all these samples, it is encouraging to 
see such a high number of tRFs being consistently present across collections. This observation coupled to the 
demonstrated tissue specificity of tRFs suggests that devising tRF-based biomarkers for this cancer or for other 
types of cancer is a real possibility.
Discussion
In recent work, we identified potential roles for miRNAs/isomiRs and tRFs as tissue- and patient-specific 
post-transcriptional regulators. Here, we characterized the tRF and isomiR profiles of 526 human prostate sam-
ples from TCGA and examined whether these molecules exhibit differential abundance in disease compared to 
normal and whether there is a race-specific component to the abundance of these molecules. Our analyses also 
investigated the correlations between isomiRs and mRNAs, and between tRFs and mRNAs, to elucidate putative 
regulatory connections between these short non-coding RNAs and the post-transcriptional regulation layer that 
is at work in prostate.
Figure 7. Correlation networks for isomiR-mRNA and tRF-mRNA relationships. We sub-selected differentially 
abundant isomiRs and tRFs and kept only those with mean abundance ≥1 RPM across all 526 datasets. We 
computed Spearman correlations isomiRs and tRFs and those mRNAs whose mean RPKM was ≥ 1/1024 of 
the largest abundance observed for ACTB as measured by sequenced reads. (A) isomiR-mRNA correlations. 
(B) tRF-mRNA correlations. In panels A and B, ncRNA nodes were collapsed to the name of the contributing 
miRNA locus (orange) or tRNA isodecoder (grey), respectively. Blue nodes represent mRNAs. In both panels, 
only correlations with an absolute value ≥ 0.33 and an FDR ≤ 5% were retained and shown. Green edges: 
positive correlations. Red edges: negative correlations.
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Our analyses showed that the TCGA PRAD datasets are characterized by very rich tRF profiles. Interestingly, 
these profiles are largely similar to tRF profiles that we generated by analyzing two different cohorts1,41, suggesting 
a consistency of tRF profiles in prostate tumors across likely diverse populations. Arguably, the 923 tRFs that we 
identified as being present in all three cohorts represent a good starting point for researchers interested in study-
ing the roles of these molecules in the prostate context.
DAVID analyses of the mRNAs that are correlated with isomiRs and tRFs reveal interesting potential roles for 
each of these two classes of regulators in disease. When we filtered our correlations by retaining only those with 
predicted miRNA target interactions from all 4 different algorithms, our mRNA input list led to an enrichment 
for GO terms relating to metabolic and biosynthetic processes. When we filtered isomiRs based on the strength of 
anticorrelation with mRNAs (r ≤ −0.33), pathways that are critical for the production of mature mRNA products 
were enriched instead, including: mRNA processing, RNA splicing, mRNA splicing via spliceosome, RNA meta-
bolic process, and mRNA metabolic process.
We also find specific GO enrichments for isomiR-mRNA correlations with isomiRs that were differentially 
expressed between PRAD Wh and PRAD B/Aa samples. Specifically, GO enrichments from these 93 mRNAs 
pertain to reproductive pathways and are characterized by an overabundance of androgen receptor signaling 
machinery genes. Future work should look to determine whether isomiRs could play a race-independent role 
in PRAD biology, as well as whether they could influence the variability of androgen receptor activity seen in 
different race groups.
For tRFs that are differentially abundant between normal prostate and PRAD (both races), we found 
that correlated mRNAs enriched in GO terms pertaining to cellular responses to stimuli. These terms 
include: GO:0071495-cellular response to endogenous stimulus, GO:0009719-response to endogenous 
stimulus, GO:0010033-response to organic substance, GO:0032870-cellular response to hormone stimu-
lus, and GO:0009725-response to hormone. We note that the large majority of tRFs are positively correlated 
with mRNAs and that negative correlations between tRFs and mRNAs do not significantly contribute to GO 
enrichments.
Collectively, these findings raise the possibility of a disease biology in which dysregulation of miRNAs/
isomiRs might give rise to accumulating oncogenic transcripts, whereas dysregulation of tRFs might render cells 
insensitive to control signals in the microenvironment. Specifically, isomiRs may be involved in regulating nucleic 
acid and protein metabolism or may be involved in regulating splicing machinery. Losing these isomiRs in pros-
tate cancer contexts may contribute to the accumulation of alternatively spliced oncogenic transcripts that both 
contribute to disease progression and account for some differential characteristics of disease54,55. Alternatively, 
isomiRs may accumulate or be co-regulated with mRNAs involved in upregulation of the proliferative pathways 
that contribute to tumor biology – i.e., those involved in nuclear division, cell cycle processes, or metabolism 
(see above). tRFs might be produced in cells actively responding to metabolic changes in the microenviron-
ment or to paracrine/autocrine signaling, whereas isomiRs might become dysregulated in cells experiencing 
pro-proliferative or cancerous transformations driven by other mechanisms. We note here that tRNA halves have 
been reported to be produced in response to hormone signaling23. Follow-up studies will need to establish causal 
relationships from these correlations. The investigation of a possible regulatory relationship between these two 
groups of ncRNAs and prostate cancer specific gene pathways is warranted.
Our findings suggest the possibility of developing a deep-sequencing-based approach that examines the abun-
dance of a specific subset of short ncRNAs and allows the automated detection of prostate cancer. This would 
enable diagnosis in a manner that is minimally dependent on human observation. It is important to note here 
that our earlier findings indicate that it may not be feasible to base such a diagnosis on qRT-PCR techniques 
aimed at estimating the abundance of specific isomiRs or tRFs. Indeed, as we showed, the simultaneous presence 
of near-identical variants of the targeted isomiR or tRF introduces cross-talk that skews these measurements48.
In terms of prioritizing future work, we believe that initial efforts should be directed at elucidating the bio-
genesis and functional roles of these molecules. Doing so will have a direct beneficial impact when designing 
experiments to study these molecules. In the absence of this knowledge, it is difficult to know the extent to which 
attempts to over-express or silence a tRF disrupt other cellular processes leading to unintended consequences.
Materials and Methods
Sample Collection and Patient Enrollment. The TCGA initiative enrolled all of the PRAD patients 
whose samples were analyzed in this presentation. We focused on and analyzed the short RNA profiles from 526 
prostate cancer datasets from 472 patients that were part of TCGA PRAD as of October 2015. Only samples that 
were ‘white-listed’ by the PRAD consortium were analyzed, meaning that these samples did not bear an annota-
tion calling for their exclusion from the TCGA PRAD project. We also included 10 samples from an independent 
dataset first discussed in1, which includes deep sequencing from 5 prostate cancer tumor tissue samples, as well 
as 5 normal prostate tissue controls. We further included 11 datasets that represent pooled prostate tissue RNA 
samples from 11 patient groups, including one FFPE tumor preserved sample set and one normal healthy prostate 
tissue sample set.
Mapping. For the isomiR analyses, we mapped the reads on the full genome, as we previously described13,15,20. 
For the tRF analyses, we used the MINTmap tool we reported recently56 to mine for and quantify tRFs. The 
mRNA data were generated by the TCGA initiative and downloaded from the rsem.genes.normalized_expression 
files generated as output of the UNC mRNA analysis pipeline. All mRNA values represent RPKM values as com-
puted by the RSEM RNA-seq analysis platform.
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Data Thresholds and Normalization. After mapping, and for each of the 526 TCGA samples in turn, 
we thresholded isomiRs and tRFs using the Threshold-seq method42. Read counts were normalized to Reads Per 
Million (RPM) by referring to the number of reads that survive quality trimming and adapter removal.
Statistical Analyses. We used the R software package for statistical analyses. We used the prcomp package 
for PCA analysis57 and the samr package for the Significance Analysis of Microarrays46. Plots were generated 
using the gplots, matplotlib and igraph packages.
miRNA Target Prediction. We used TargetScan 7.150, miRanda50, RNAhybrid52, and rna2258 (http://cm.jef-
ferson.edu/rna22/) to generate miRNA target predictions. We sought targets in the 3′UTRs of mRNAs in all four 
tools. We used mRNAs and isomiRs that were negatively correlated in our data for predictions in all tools.
DAVID Functional Analysis. GO term enrichments were computed using DAVID59, with an FDR threshold 
of less than or equal to 1%59 (Release 6.8 of October 2016). We performed functional analysis first using mRNAs 
that are predicted as targets of isomiRs with which they are negatively correlated. We considered only targets pre-
dicted by all four prediction tools. For comparison purposes, we also performed functional analysis using those 
mRNAs that were negatively correlated with isomiRs with correlation value less than or equal to −0.33.
Data Availability. The TCGA datasets that are described in this study are available from The Cancer 
Genome Atlas data portal at: https://portal.gdc.cancer.gov/. The deep sequencing datasets from normal prostate 
and PRAD originally discussed in our previous work1 are available at http://trace.ddbj.nig.ac.jp/DRASearch/
study?acc = SRP034550. The data of the earlier prostate cancer study41 are available through GEO accession 
GSE80400. All of the data that we generated in our analyses are included in the Supplemental material accompa-
nying this manuscript.
Declarations. Ethics approval and consent to participate. Not applicable for the TCGA datasets. For the 
other two datasets, see previous publications1,41.
Availability of data and materials. The original datasets that we used and/or analyzed during the current 
study are available from The Cancer Genome Atlas data portal at: https://portal.gdc.cancer.gov/. The alternative 
datasets are available through http://trace.ddbj.nig.ac.jp/DRASearch/study?acc = SRP034550 and through GEO 
accession GSE80400.
References
 1. Londin, E. et al. Analysis of 13 Cell Types Reveals Evidence for the Expression of Numerous Novel Primate- and Tissue-Specific 
microRNAs. Proceedings of the National Academy of the Sciences 112, E1106–E1115 (2014).
 2. Friedlander, M. R. et al. Discovering microRNAs from Deep Sequencing Data Using miRDeep. Nature Biotechnology 26, 407–415 
(2008).
 3. Bartel, D. P. MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. Cell 116, 281–297 (2004).
 4. Iorio, M. V. & Croce, C. M. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. 
EMBO Mol Med 4, https://doi.org/10.1002/emmm.201100209 (2012).
 5. Kayani, M., Kayani, M. A., Malik, F. A. & Faryal, R. Role of miRNAs in breast cancer. Asian Pac J Cancer Prev 12 (2011).
 6. Lee, Y. S. & Dutta, A. MicroRNAs in cancer. Annu Rev Pathol 4, https://doi.org/10.1146/annurev.pathol.4.110807.092222 (2009).
 7. Leva, G. & Croce, C. M. miRNA profiling of cancer. Curr Opin Genet Dev 23, https://doi.org/10.1016/j.gde.2013.01.004 (2013).
 8. Lu, J. et al. MicroRNA expression profiles classify human cancers. Nature 435, https://doi.org/10.1038/nature03702 (2005).
 9. Griffiths-Jones, S. The microRNA Registry. Nucleic Acids Research 32, D109–D111 (2004).
 10. Ambros, V. et al. A Uniform System for microRNA Annotation. RNA 9, 277–279 (2003).
 11. Morin, R. D. et al. Application of Massively Parallel Sequencing to microRNA Profiling and Discovery in Human Embryonic Stem 
Cells. Genome Research 18, 610–621 (2008).
 12. Koppers-Lalic, D. et al. Non-invasive Prostate Cancer Detection by Measuring miRNA Variants (isomiRs) in Urine Extracellular 
Vesicles. Oncotarget 7, 22566–22578 (2016).
 13. Loher, P., Londin, E. & Rigoutsos, I. IsomiR Expression Profiles in Human Lymphoblastoid Cell Lines Exhibit Population and 
Gender Dependencies. Oncotarget 5, 8790–8802 (2014).
 14. Griffiths-Jones, S., Grocock, R. J., van Dongen, S., Bateman, A. & Enright, A. J. miRBase: microRNA Sequences, Targets and Gene 
Nomenclature. Nucleic Acids Research 34, D140–D144 (2006).
 15. Telonis, A. G., Loher, P., Jing, Y., Londin, E. & Rigoutsos, I. Beyond the One-Locus-One-miRNA Paradigm: microRNA Isoforms 
Enable Deeper Inisights into Breast Cancer Heterogeneity. Nucleic Acids Research 43, 9158–9175 (2015).
 16. Telonis, A. G. et al. Knowledge about the presence or absence of miRNA isoforms (isomiRs) can successfully discriminate amongst 
32 TCGA cancer types. Nucleic Acids Res 45, 2973–2985, https://doi.org/10.1093/nar/gkx082 (2017).
 17. Sobala, A. & Hutvagner, G. Transfer RNA-Derived Fragments: Origins, Processing, and Functions. Wiley Interdisciplinary Reviews 
RNA 2, 853–862 (2011).
 18. Anderson, P. & Ivanov, P. tRNA Fragments in Human Health and Disease. FEBS Letters 588, 4297–4304 (2014).
 19. Shigematsu, M., Honda, S. & Kirino, Y. Transfer RNA as a Source of Small Functional RNA. Journal of Molecular Biological Molecular 
Imaging 1, 8 (2014).
 20. Telonis, A. G. et al. Dissecting tRNA-Derived Fragment Complexities Using Personalized Transcriptomes Reveals Novel Fragment 
Classes and Unexpected Dependencies. Oncotarget 6, 24797–24822 (2015).
 21. Fu, H. et al. Stress Induces tRNA Cleavage by Angiogenin in Mammalian Cells. FEBS Letters 583, 437–442 (2009).
 22. Yamasaki, S., Ivanov, P., Hu, G.-F. & Anderson, P. Angiogenin Cleaves tRNA and Promotes Stress-Induced Translation Repression. 
Journal of Cell Biology 185, 35–42 (2009).
 23. Honda, S. et al. Sex Hormone-Dependent tRNA Halves Enhance Cell Proliferation in Breast and Prostate Cancers. Proceedings of the 
National Academy of the Sciences 112, E3816–3825 (2015).
 24. Li, Z. et al. Extensive Terminal and Asymmetric Processing of Small RNAs from rRNAs, snoRNAs, snRNAs, and tRNAs. Nucleic 
Acids Research 40, 6787–6799 (2012).
 25. Cole, C. et al. Filtering of Deep Sequencing Data Reveals the Existence of Abundant Dicer-Dependent Small RNAs Derived from 
tRNAs. RNA 15, 2147–2160 (2009).
www.nature.com/scientificreports/
1 2Scientific RepoRts |  (2018) 8:5314  | DOI:10.1038/s41598-018-22488-2
 26. Maute, R. L. et al. tRNA-Derived microRNA Modulates Proliferation and the DNA Damage Response and is Down-Regulated in B 
Cell Lymphoma. Proceedings of the National Academy of the Sciences 110, 1404–1409 (2013).
 27. Kumar, P., Ananya, J., Mudunuri, S. B. & Dutta, A. Meta-analysis of tRNA Derived RNA Fragments Reveals That They Are 
Evolutionarily Conserved and Associate with AGO Proteins to Recognize Specific RNA Targets. BMC Biology 12, online (2014).
 28. Selitsky, S. R. et al. Small tRNA-Derived RNAs Are Increased and More Abundant Than MicroRNAs in Chronic Hepatitis B and C. 
Scientific Reports 5, 7675 (2015).
 29. Goodarzi, H. et al. Endogenous tRNA-Derived Fragments Suppress Breast Cancer Progression Via YBX1 Displacement. Cell 161, 
709–802 (2015).
 30. Ivanov, P., et al. G-Quadruplex Structures Contribute to the Neuroprotective Effects of Angiogenin-Induced tRNA Fragments. 
Proceedings of the National Academy of the Sciences 111, 18201-18206 (2014).
 31. Li, Q., et al. tRNA-Derived Small Non-Coding RNAs in Response to Ischemia InhibitAngiogenesis. Scientific Reports 6, online 
(2016).
 32. Consortium, T. C. G. A. The Molecular Taxonomy of Primary Prostate. Cancer. Cell 163, 1011–1025 (2015).
 33. Cooperberg, M. Re-Examining Racial Disparities in Prostate Cancer Outcomes. Journal of Clinical Oncology 31, 2979–2980 (2013).
 34. Eble, M. Complications from Treatment of Localised Prostate Cancer. Lancet Oncology 15, 134–135 (2014).
 35. Nam, R. K. et al. Incidence of Complications Other Than Urinary Incontinence or Erectile Dysfunction After Radical Prostatectomy 
or Radiotherapy for Prostate Cancer: A Population Based Cohort Study. Lancet Oncology 15, 223–231 (2014).
 36. Bosset, J. F. et al. Fluorouracil-Based Adjuvant Chemotherapy After Preoperative Chemoradiotherapy in Rectal Cancer: Long-Term 
Results of the EORTC 22921 Randomised Study. Lancet Oncology 15, 184–190 (2014).
 37. Barrington, W. E. et al. Difference in Association of Obesity with Prostate Cancer Risk Between US African American and Non-
Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the American Medical Assocation 
Oncology 1, 342–349 (2015).
 38. D’Amico, A. V. Treatment or Monitoring for Early Prostate Cancer. New England Journal of Medicine 0, null, https://doi.org/10.1056/
NEJMe1610395 (2016).
 39. Hoffman, R. M. et al. Racial and Ethnic Differences in Advanced-Stage Prostate Cancer: the Prostate Cancer Outcomes Study. 
Journal of National Cancer Institute 93, 388–395 (2001).
 40. Khierandish, P. & Chinegwundow, F. Ethnic Differences in Prostate Cancer. British Journal of Cancer 105, 481–485 (2011).
 41. Olvedy, M. et al. A Comprehensive Repertoire of tRNA-Derived Fragments in Prostate Cancer. Oncotarget 7, 24766–24777 (2016).
 42. Magee, R., Loher, P., Londin, E. & Rigoutsos, I. Threshold-seq: a tool for determining the threshold in short RNA-seq datasets. 
Bioinformatics, https://doi.org/10.1093/bioinformatics/btx073 (2017).
 43. Tan, G. C. et al. 5′ isomiR variation is of functional and evolutionary importance. Nucleic Acids Research, https://doi.org/10.1093/
nar/gku656 (2014).
 44. Baran-Gale, J., Fannin, E. E., Kurtz, C. L. & Sethupathy, P. Beta Cell 5′-Shifted isomiRs Are Candidate Regulatory Hubs in Type 2 
Diabetes. PLoS ONE 8, e73240, https://doi.org/10.1371/journal.pone.0073240 (2013).
 45. Manzano, M., Forte, E., Raja, A. N., Schipma, M. J. & Gottwein, E. Divergent target recognition by coexpressed 5′-isomiRs of miR-
142-3p and selective viral mimicry. RNA 21, 1606–1620, https://doi.org/10.1261/rna.048876.114 (2015).
 46. Tusher, V. G., Tibshirani, R. & Chu, G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad 
Sci USA 98, 5116–5121, https://doi.org/10.1073/pnas.091062498 (2001).
 47. Epstein, J. I. et al. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. Eur Urol 69, 
428–435, https://doi.org/10.1016/j.eururo.2015.06.046 (2016).
 48. Magee, R. et al. Assessment of isomiR Discrimination Using Commercial qPCR Methods. Non-Coding RNA 3 (2017).
 49. Pliatsika, V., Loher, P., Telonis, A. G. & Rigoutsos, I. MINTbase: a framework for the interactive exploration of mitochondrial and 
nuclear tRNA fragments. Bioinformatics 32, 2481–2489, https://doi.org/10.1093/bioinformatics/btw194 (2016).
 50. Telonis, A. G. et al. Dissecting tRNA-derived fragment complexities using personalized transcriptomes reveals novel fragment 
classes and unexpected dependencies. Oncotarget 6, 24797–24822, https://doi.org/10.18632/oncotarget.4695 (2015).
 51. Lewis, B. P., Burge, C. B. & Bartel, D. P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human 
genes are microRNA targets. Cell 120, 15–20, https://doi.org/10.1016/j.cell.2004.12.035 (2005).
 52. Miranda, K. C. et al. A pattern-based method for the identification of MicroRNA binding sites and their corresponding 
heteroduplexes. Cell 126, 1203–1217, https://doi.org/10.1016/j.cell.2006.07.031 (2006).
 53. Kruger, J. & Rehmsmeier, M. RNAhybrid: microRNA target prediction easy, fast and flexible. Nucleic Acids Res 34, W451–454, 
https://doi.org/10.1093/nar/gkl243 (2006).
 54. Rajan, P., Elliott, D. J., Robson, C. N. & Leung, H. Y. Alternative splicing and biological heterogeneity in prostate cancer. Nat Rev Urol 
6, 454–460, https://doi.org/10.1038/nrurol.2009.125 (2009).
 55. Wang, B. D. et al. Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer. Nat 
Commun 8, 15921, https://doi.org/10.1038/ncomms15921 (2017).
 56. Loher, P., Telonis, A. G. & Rigoutsos, I. MINTmap: fast and exhaustive profiling of nuclear and mitochondrial tRNA fragments from 
short RNA-seq data. Sci Rep 7, 41184, https://doi.org/10.1038/srep41184 (2017).
 57. Sigg, C. D. & Buhmann, J. M. Expectation-Maximization for Sparse and Non-Negative PCA. Proceedings of the 25th International 
Conference on Machine Learning (2008).
 58. Loher, P. & Rigoutsos, I. Interactive exploration of RNA22 microRNA target predictions. Bioinformatics 28, 3322–3323, https://doi.
org/10.1093/bioinformatics/bts615 (2012).
 59. Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics 
resources. Nat Protoc 4, 44–57, https://doi.org/10.1038/nprot.2008.211 (2009).
Acknowledgements
This work was supported by NIH/NCI grant R21-CA195204 (IR), a W. M. Keck Foundation grant (IR), and by 
Institutional funds.
Author Contributions
I.R. designed and supervised the study. R.M., A.G.T. and P.L. downloaded and collected the data. P.L. mapped 
the data. R.M., A.G.T. and I.R. analyzed the data. R.M., I.R. and E.L. wrote the manuscript. All authors read and 
approved the final manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-22488-2.
Competing Interests: The authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
www.nature.com/scientificreports/
13Scientific RepoRts |  (2018) 8:5314  | DOI:10.1038/s41598-018-22488-2
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
